2025
Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes
Puzo C, Siddon A. Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes. Pathology 2025 DOI: 10.1016/j.pathol.2024.12.632.Peer-Reviewed Original ResearchLineage specific chimerismChimerism testingMyeloid malignanciesCell burdenHematopoietic cellsPost allogeneic stem cell transplantationHost hematopoietic cellsMalignant cell burdenLeukemic cell burdenStem cell transplantationRisk of relapseRecipient hematopoietic cellsPost-transplant outcomesCell transplantationRelapse detectionRecipient chimerismTherapy decisionsRelapsePercentage of donorsChimerismHigh riskConcurrent useChimerism percentageEarly identificationMalignancy
2023
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
Lee T, Aisner D, David M, Eno C, Gagan J, Gocke C, Guseva N, Haley L, Jajosky A, Jones D, Mansukhani M, Mroz P, Murray S, Newsom K, Paulson V, Roy S, Rushton C, Segal J, Senaratne T, Siddon A, Starostik P, Van Ziffle J, Wu D, Xian R, Yohe S, Kim A. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances 2023, 7: 4599-4607. PMID: 37236162, PMCID: PMC10425685, DOI: 10.1182/bloodadvances.2023010149.Peer-Reviewed Original ResearchConceptsMolecular testingAcute casesHematologic malignanciesRapid turnaround timeTertiary care laboratoryAcute myeloid leukemiaCurrent clinical practiceMyeloid leukemiaTurnaround timeLymphoid processesClinical practicePatient careNGS panelCalendar daysClinical expectationsWorking Group ReportMost survey respondentsMalignancyCareReimbursementCase reimbursementSurvey respondentsGroup ReportTesting practicesDays